Literature DB >> 17854720

How can hepatitis C be prevented in the long term?

Pedro Mateu-Gelabert1, Carla Treloar, Víctor Agulló Calatayud, Milagros Sandoval, Juan Carlos Valderrama Zurián, Lisa Maher, Tim Rhodes, Samuel R Friedman.   

Abstract

Significant advances have been made in preventing HIV infection among injectors but we still know little about preventing hepatitis C (HCV). Both prevalence and incidence of hepatitis C can remain high among IDUs even in the context of widespread implementation of harm reduction programmes. We need to develop new ways to fill the knowledge gap regarding HCV prevention. One way is to learn from the experts--those IDUs who, after long-term injection in social milieus of high hepatitis C prevalence, nonetheless remain uninfected. We describe a recently commenced program of research that focuses on understanding the strategies, behaviours, and environmental factors associated with "staying safe". This represents a 180-degree turn in IDU research where the focus has traditionally been on risk. Since social, cultural and environmental factors, as well as the vagaries of human strategic discovery by drug users can vary among localities, researchers in four different contexts--New York City, Valencia, Sydney and London--are collaborating in parallel Staying Safe studies. These studies aim to provide the conceptual basis for developing a new generation of HCV prevention programs to assist both new and experienced IDUs to remain uninfected over the long run.

Entities:  

Mesh:

Year:  2007        PMID: 17854720      PMCID: PMC2117625          DOI: 10.1016/j.drugpo.2007.06.001

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  17 in total

1.  Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study.

Authors:  Ali Judd; Matthew Hickman; Steve Jones; Tamara McDonald; John V Parry; Gerry V Stimson; Andrew J Hall
Journal:  BMJ       Date:  2004-11-12

Review 2.  Transmission of hepatitis C virus: rates, routes, and cofactors.

Authors:  M MacDonald; N Crofts; J Kaldor
Journal:  Epidemiol Rev       Date:  1996       Impact factor: 6.222

3.  Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment.

Authors:  Lorna E Thorpe; Lawrence J Ouellet; Ronald Hershow; Susan L Bailey; Ian T Williams; John Williamson; Edgar R Monterroso; Richard S Garfein
Journal:  Am J Epidemiol       Date:  2002-04-01       Impact factor: 4.897

Review 4.  HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention.

Authors:  Holly Hagan; Hanne Thiede; Don C Des Jarlais
Journal:  AIDS       Date:  2005-10       Impact factor: 4.177

5.  Methadone maintenance and hepatitis C virus infection among injecting drug users.

Authors:  N Crofts; L Nigro; K Oman; E Stevenson; J Sherman
Journal:  Addiction       Date:  1997-08       Impact factor: 6.526

6.  Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.

Authors:  Lisa Maher; Bin Jalaludin; Kerry G Chant; Rohan Jayasuriya; Tim Sladden; John M Kaldor; Penny L Sargent
Journal:  Addiction       Date:  2006-10       Impact factor: 6.526

7.  Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area.

Authors:  H Thiede; H Hagan; C S Murrill
Journal:  J Urban Health       Date:  2000-09       Impact factor: 3.671

8.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

9.  Incidence rate and risk factors for HCV seroconversion among injecting drug users in an area with low HIV seroprevalence.

Authors:  G Rezza; L Sagliocca; M Zaccarelli; M Nespoli; M Siconolfi; C Baldassarre
Journal:  Scand J Infect Dis       Date:  1996

10.  Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France.

Authors:  D Lucidarme; A Bruandet; D Ilef; J Harbonnier; C Jacob; A Decoster; C Delamare; C Cyran; A F Van Hoenacker; D Frémaux; P Josse; J Emmanuelli; Y Le Strat; J C Desenclos; B Filoche
Journal:  Epidemiol Infect       Date:  2004-08       Impact factor: 2.451

View more
  14 in total

1.  Correlates of staying safe behaviors among long-term injection drug users: psychometric evaluation of the staying safe questionnaire.

Authors:  Peter Vazan; Pedro Mateu-Gelabert; Charles M Cleland; Milagros Sandoval; Samuel R Friedman
Journal:  AIDS Behav       Date:  2012-08

2.  [Injecting without getting infected: injectors' strategies to prevent HIV and HCV.]

Authors:  P Mateu-Gelabert; S Friedman; M Sandoval
Journal:  Trastor Adict       Date:  2007-10-01

Review 3.  A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

Review 4.  Group sex events amongst non-gay drug users: an understudied risk environment.

Authors:  Samuel R Friedman; Pedro Mateu-Gelabert; Milagros Sandoval
Journal:  Int J Drug Policy       Date:  2010-08-25

5.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users.

Authors:  Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

6.  Strategies to avoid opiate withdrawal: implications for HCV and HIV risks.

Authors:  Pedro Mateu-Gelabert; Milagros Sandoval; Peter Meylakhs; Travis Wendel; Samuel R Friedman
Journal:  Int J Drug Policy       Date:  2009-09-27

7.  The staying safe intervention: training people who inject drugs in strategies to avoid injection-related HCV and HIV infection.

Authors:  Pedro Mateu-Gelabert; Marya Viorst Gwadz; Honoria Guarino; Milagros Sandoval; Charles M Cleland; Ashly Jordan; Holly Hagan; Howard Lune; Samuel R Friedman
Journal:  AIDS Educ Prev       Date:  2014-04

8.  Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injection.

Authors:  P Roux; L Fugon; J D Jones; S D Comer
Journal:  Am J Addict       Date:  2013-06-06

9.  Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Authors:  Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2017-07-03

10.  The Cedar Project: high incidence of HCV infections in a longitudinal study of young Aboriginal people who use drugs in two Canadian cities.

Authors:  Patricia M Spittal; Margo E Pearce; Negar Chavoshi; Wayne M Christian; Akm Moniruzzaman; Mary Teegee; Martin T Schechter
Journal:  BMC Public Health       Date:  2012-08-09       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.